Skip to main content
. 2023 May 8;8(9):e157191. doi: 10.1172/jci.insight.157191

Figure 5. Augmenting BDNF in CMT2D muscles restores in vivo axonal transport.

Figure 5

(A) Endosome frame-to-frame speed histograms of wild-type and GarsC201R/+ mice aged 1 and 3 months 4–8 hours posttreatment with intramuscular BDNF injections. (B) BDNF rescues in vivo axonal transport of signaling endosomes in GarsC201R/+ mice (P = 0.875, 1-way ANOVA). (C) BDNF corrects transport in 1-month-old GarsΔETAQ/+ mice (P < 0.001, 1-way ANOVA). (D and E) The axonal transport impairment induced by human CMT2D-causing GlyRS is prevented by exogenous recombinant BDNF (E, P < 0.001 Kruskal-Wallis test). Mice were aged 1 month. For all graphs, *P < 0.05, **P < 0.01, ***P < 0.001, Šídák’s/Dunn’s multiple comparisons test; n = 4–6. See Supplemental Figure 8.